Regenxbio’s gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.
Latest Ratings for RGNX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | SVB Leerink | Maintains | Market Perform | |
| Feb 2022 | SVB Leerink | Maintains | Market Perform | |
| Jan 2022 | SVB Leerink | Maintains | Market Perform |
